These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30676672)

  • 1. Oncogenic KRAS hotspot mutations are rare in IDH-mutant gliomas.
    Schittenhelm J; Krischker N; Gepfner-Tuma I; Behling F; Noell S; Eckert F; Biskup S; Tabatabai G
    Brain Pathol; 2019 May; 29(3):321-324. PubMed ID: 30676672
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
    Friedrich M; Bunse L; Wick W; Platten M
    Curr Opin Oncol; 2018 Nov; 30(6):368-374. PubMed ID: 30102604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of isocitrate dehydrogenase in glioma.
    Alexander BM; Mehta MP
    Expert Rev Neurother; 2011 Oct; 11(10):1399-409. PubMed ID: 21955197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
    Guo C; Pirozzi CJ; Lopez GY; Yan H
    Curr Opin Neurol; 2011 Dec; 24(6):648-52. PubMed ID: 22002076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism: reprogramming metabolic flux in glioma.
    Lokody I
    Nat Rev Cancer; 2014 Nov; 14(11):706-7. PubMed ID: 25291294
    [No Abstract]   [Full Text] [Related]  

  • 12. IDH1 mutations in gliomas: when an enzyme loses its grip.
    Frezza C; Tennant DA; Gottlieb E
    Cancer Cell; 2010 Jan; 17(1):7-9. PubMed ID: 20129244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial erosion on under-methylated regions and chromatin reprogramming contribute to oncogene activation in IDH mutant gliomas.
    Wang X; Dai L; Liu Y; Li C; Fan D; Zhou Y; Li P; Kong Q; Su J
    Epigenetics Chromatin; 2023 Apr; 16(1):13. PubMed ID: 37118755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
    Lu VM; McDonald KL
    CNS Oncol; 2018 Jan; 7(1):41-50. PubMed ID: 29303363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance metabolic imaging of glioma.
    Metellus P; Figarella-Branger D
    Sci Transl Med; 2012 Jan; 4(116):116ps1. PubMed ID: 22238331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH-1R132H mutation status in diffuse glioma patients: implications for classification.
    Wang PF; Liu N; Song HW; Yao K; Jiang T; Li SW; Yan CX
    Oncotarget; 2016 May; 7(21):31393-400. PubMed ID: 27120786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-evaluation of nondiagnostic biopsies of suspected low-grade glioma using isocitrate dehydrogenase 1 mutation immunohistochemistry.
    Anderson MD; Abel TW; Moots PL
    Neuro Oncol; 2013 Jul; 15(7):811-3. PubMed ID: 23737489
    [No Abstract]   [Full Text] [Related]  

  • 20. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.